Newsletter

QUAD Lands $450 Million Contract

On September 20, Quad Graphics reported that it landed a $450 million printing contract. The Minnesota-based company will print all catalogs for the online retailer and fellow Minnesotans, Bluestem Brands, Inc.   The news triggered a level 3 Jet Equities alert at 4:05 pm. The next trade occurred at 4:13 pm in after-hours trading for […]

0Comments

LCI Receives FDA Approval for New Drug

Lannett Company (LCI) announced on September 27 that is had received FDA approval for a new drug. The Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg are the therapeutic equivalent to the drug Percocet. U.S. sales of Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg totaled around […]

0Comments

ALJ Regional Holdings Purchases New Printing Facilities

On September 20, Phoenix Color Corp, a wholly owned subsidiary of ALJ Regional Holdings, entered into an asset purchase agreement with LSC Communications and Moore-Langen Printing. In the agreement, ALJ will obtain printing and manufacturing facilities in Terre Haute, Indiana.   Jet Equities sent a level 3 alert to its subscribers at 7:01 am on […]

0Comments

SAGE Clinical Trial Fails

Sage Therapeutics announced disappointing results on its late-stage clinical trial of a brexanolone treament for a seizure disorder called super-refractory status epilepticus (SRSE). Right now there is no U.S. drug approved for the condition. Jet Equities caught the news at 6:15 am with a level 2 alert before the stock price fell from $88.22 to […]

0Comments

Five-Day Trend Shows Markets Like HK Divestiture Plans

On September 20, Halcon Resources (HK) announced plans to divest its remaining non-operated oil assets in the Williston Basin to an undisclosed company for $104 million. Halcon started selling assets in the Williston Basin earlier this year in order to pay down its debt and focus on its operations in the Delaware Basin.   Jet […]

0Comments

ALNM Holds Gains Over Five Days

Alnylam Pharmaceuticals reported exciting stage 3 clinical trial results on September 20. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year.   Jet Equities sent out a level 2 alert at 7 am, and the next trade was at $93.50 during pre-market […]

0Comments

PDL BioPharma Announces Stock Repurchase

PDL BioPharma (PDLI) announced on September 25 that its board of directors authorized a new stock repurchase program. PDL will be able to purchase up to $25 million worth of its common stock. The company has a market cap of $500 million, so this repurchase amounts to about 5% of the total outstanding shares.   […]

0Comments

Wabco Continues Upward Trend for Five Days

On September 18, Wabco Holdings (WBC) announced its plans to buyout its joint venture partner, Meritor, Inc. WBC is a commercial vehicle supplier and believes this move will allow the company to expand its presence in the North American market.   Jet Equities sent out a level 3 alert at 6:30 am to its subscribers. […]

0Comments

Five-Day Upward Price Trend Follows TSG Guidance Update

On September 15, The Stars Group provided updated guidance for the year that included revenue growth of between 11 and 14% over last year. The company also announced its plan to prepay a $75 million second lien debt.   The news triggered a level 3 Jet Equities alert at 6:31 am, and the next trade […]

0Comments